The use of JAK inhibitors and the impact of comorbidities
Rheumatology (Oxford)
.
2024 Feb 1;63(2):273-274.
doi: 10.1093/rheumatology/kead469.
Authors
Fabiola Atzeni
1
,
Alessandra Alciati
2
3
Affiliations
1
Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
2
Department of Clinical Neurosciences, Villa S. Benedetto Menni, Albese, Como, Italy.
3
Humanitas Clinical and Research Center, Rozzano, Italy.
PMID:
37672019
DOI:
10.1093/rheumatology/kead469
No abstract available
MeSH terms
Arthritis, Rheumatoid*
Comorbidity
Humans
Janus Kinase Inhibitors* / pharmacology
Janus Kinase Inhibitors* / therapeutic use
Janus Kinases
Substances
Janus Kinase Inhibitors
Janus Kinases